Breast Cancer Coverage from Every Angle

Melinda L. Telli, MD, on Choosing Among Many Treatment Options for HER2-Positive Breast Cancer

Posted: Wednesday, April 14, 2021

Melinda L. Telli, MD, of Stanford Cancer Institute, discusses how the updated NCCN Clinical Practice Guidelines in Oncology® can help physicians approach treatment decisions for individual patients with HER2-positive breast cancer, given the many options now available, including tucatinib, margetuximab, trastuzumab, and neratinib.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.